Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Look for the Union Label

This article was originally published in RPM Report

Executive Summary

The sales of Chrysler may mean more to pharma than new leases on company cars. If new management is serious about cutting costs, that could mean big changes to union contracts. The autoworker contracts have helped set the standards for public benefits for two decades--so any changes would have a big impact.

You may also be interested in...



Reinventing Pharmacy: The Bidding for Caremark is Just the Beginning

The battle between CVS and Express Scripts for ownership of Caremark has made little impact on drug-company executives. But there is an important implication for pricing in the Medicare Part D world: CVS wants to use Caremark to help it get higher payments for providing pharmacy services. But in the zero-sum game of reimbursement, any additional profits for chains will likely come from reduced prices on drugs.

Part D: A Big Chance for Small PBMs

Smaller PBMs are making bigger bets on the new Medicare drug market. Companies like RxAmerica, CVS/Pharmacare and Argus think their business models give them an edge over the "big three" pharmacy benefit managers in this major new market. If they are right, it could transform the entire US pharma sector.

US FDA’s Biggest Post-COVID Challenge May Be Helped By Small Inspections Tweak In FDORA

The omnibus spending bill included dozens of reform provisions related to the US FDA. One seemingly minor change to FDA’s inspection authorities could end up being a big help to the challenges ahead in catching up after the COVID-19 pandemic.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS080297

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel